ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Tempest Therpeutics Inc

Tempest Therpeutics Inc (TPST)

0.914
0.0092
( 1.02% )
Updated: 14:56:34

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.914
Bid
0.9079
Ask
0.92
Volume
305,723
0.89 Day's Range 0.9199
0.6986 52 Week Range 6.00
Market Cap
Previous Close
0.9048
Open
0.89
Last Trade
5000
@
0.914
Last Trade Time
14:56:34
Financial Volume
$ 274,966
VWAP
0.899395
Average Volume (3m)
1,632,849
Shares Outstanding
43,642,072
Dividend Yield
-
PE Ratio
-1.33
Earnings Per Share (EPS)
-0.68
Revenue
-
Net Profit
-29.49M

About Tempest Therpeutics Inc

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Tempest Therpeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TPST. The last closing price for Tempest Therpeutics was $0.90. Over the last year, Tempest Therpeutics shares have traded in a share price range of $ 0.6986 to $ 6.00.

Tempest Therpeutics currently has 43,642,072 shares outstanding. The market capitalization of Tempest Therpeutics is $39.49 million. Tempest Therpeutics has a price to earnings ratio (PE ratio) of -1.33.

TPST Latest News

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.01651.838440111420.89751.010.8528189890.92567458CS
40.0839.987966305660.8311.050.79213636320.93676528CS
12-0.0818-8.21450090380.99581.160.698616328490.90731451CS
26-0.766-45.59523809521.682.180.698631265561.19101806CS
52-2.816-75.49597855233.7360.698620475291.69085924CS
156-2.796-75.36388140163.719.770.1717027974.17117615CS
260-12.896-93.381607530813.81410.1714680414.67272482CS

TPST - Frequently Asked Questions (FAQ)

What is the current Tempest Therpeutics share price?
The current share price of Tempest Therpeutics is $ 0.914
How many Tempest Therpeutics shares are in issue?
Tempest Therpeutics has 43,642,072 shares in issue
What is the market cap of Tempest Therpeutics?
The market capitalisation of Tempest Therpeutics is USD 39.49M
What is the 1 year trading range for Tempest Therpeutics share price?
Tempest Therpeutics has traded in the range of $ 0.6986 to $ 6.00 during the past year
What is the PE ratio of Tempest Therpeutics?
The price to earnings ratio of Tempest Therpeutics is -1.33
What is the reporting currency for Tempest Therpeutics?
Tempest Therpeutics reports financial results in USD
What is the latest annual profit for Tempest Therpeutics?
The latest annual profit of Tempest Therpeutics is USD -29.49M
What is the registered address of Tempest Therpeutics?
The registered address for Tempest Therpeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Tempest Therpeutics website address?
The website address for Tempest Therpeutics is www.tempesttx.com
Which industry sector does Tempest Therpeutics operate in?
Tempest Therpeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SLXNSilexion Therapeutics Corporation
$ 3.01
(122.96%)
289.01M
DGNXDiginex Ltd
$ 29.18
(94.66%)
2.39M
KRKR36Kr Holdings Inc
$ 7.76
(82.59%)
22.16M
LGCLLucas GC Ltd
$ 0.8305
(45.19%)
41.58M
BNZIBanzai International Inc
$ 1.7546
(40.37%)
25.78M
MGOLMGO Global Inc
$ 0.1024
(-38.42%)
47.5M
ZKINZK International Group Co Ltd
$ 0.5052
(-38.29%)
2.72M
EYENEyenovia Inc
$ 0.03535
(-37.98%)
21.24M
BACKIMAC Holdings Inc
$ 0.761899
(-37.55%)
2.03M
HAOHaoxi Health Technology Ltd
$ 2.571
(-30.51%)
381.72k
NVDANVIDIA Corporation
$ 122.585
(-4.97%)
310M
SLXNSilexion Therapeutics Corporation
$ 3.01
(122.96%)
289.01M
OCEAOcean Biomedical Inc
$ 0.2718
(-17.64%)
176.6M
RIMEAlgorhythm Holdings Inc
$ 0.0273
(-11.65%)
112.44M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.463
(0.63%)
97.33M

TPST Discussion

View Posts
Ringrock Ringrock 3 weeks ago
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Source: GlobeNewswire Inc.

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR? antagonist for the treatment of patients with hepatocellular carcinoma (HCC).
β€œReceiving orphan drug designation for amezalpat to treat HCC underscores the critical need for new treatment options for patients suffering from this historically hard to treat disease,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D of Tempest. β€œTempest is dedicated to developing groundbreaking cancer treatments that will improve patients’ lives, and with broad agreement in hand from both the FDA and EMA, the team continues to prepare for a pivotal phase 3 study for amezalpat in first-line HCC patients.”

This important regulatory designation follows positive data across multiple key study efficacy and safety endpoints in a global randomized Phase 1b/2 clinical study evaluating amezalpat plus standard-of-care atezolizumab and bevacizumab versus atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic HCC. Notable positive outcomes of the randomized comparison include a six-month improvement in median overall survival (OS) with a hazard ratio (HR) of 0.65 for patients receiving the amezalpat combination therapy and an objective response rate (ORR) of 30% vs 13% favoring the amezalpat arm. In addition, survival benefit from the addition of amezalpat was preserved in key sub-populations including PD-L1 negative disease and b-catenin mutated disease, which is consistent with amezalpat’s proposed mechanism of action to target both the tumor cells directly and the patient’s immune system.
πŸ‘οΈ0
georgie18 georgie18 2 months ago
It's in the filings...🥳
👍 1
BurgerKing82 BurgerKing82 2 months ago
Do you still think R/S is coming....
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$1.09...🥳...BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received a β€œStudy May Proceed” letter from the U.S. Food and Drug Administration (FDA) to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in a pivotal randomized Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

β€œThe clinical and regulatory team at Tempest are thrilled to receive this notice from FDA with respect to the planned pivotal Phase 3 trial to evaluate amezalpat as a potential treatment for first-line liver cancer,” said Sam Whiting M.D., Ph.D., chief medical officer and head of R&D of Tempest. β€œPreviously reported positive Phase 2 data underscore amezalpat’s potential to improve the survival of patients facing this life-threatening disease, and our team is dedicated to advancing the program and bringing amezalpat to patients.”

georgie18

Member Level
Re: None

Friday, November 08, 2024 6:22:34 PM

Post#
664322
of 664538
TPST...$1.09...Chart firming up from the .85 Range Bottom...R/S coming here...🥳
πŸ‘οΈ0
aBeezlee aBeezlee 3 months ago
I sold my shares, but kept the calls.
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$1.09...Chart firming up from the .85 Range Bottom...R/S coming here...🥳
πŸ‘οΈ0
aBeezlee aBeezlee 3 months ago
Not a bad recovery. Will see if an ER or business report is released, then decide to sell or not.
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
TPST , new 52 week low
πŸ‘οΈ0
stockyupydowny stockyupydowny 3 months ago
Agreed, we will see positive news and a boost in price prior to the split..... the higher the price the lower the split IF its even required. Should they get positive news and more support from ROCHE this can rocket and then cancel split... that's moon time!
👍️ 1
georgie18 georgie18 3 months ago
We shall see...🥳
πŸ‘οΈ0
aBeezlee aBeezlee 3 months ago
1 to 2, or 1 to 15 RS. The split doesn't make sense unless a notable event is coming. Negative sentiment will simply beat it down, and kill existing holders further.

I'm under the impression dilution is coming.
πŸ‘οΈ0
georgie18 georgie18 3 months ago
Yes I did...will buy back when the dust settles...🥳...made great profit with TPST and if the reverse should happen it should put this stock in the $40...imo...we shall see...
👍 1
rocketeer357 rocketeer357 3 months ago
Did you sell on the 14a news?
πŸ‘οΈ0
georgie18 georgie18 3 months ago
You saw the 14a...🥳
πŸ‘οΈ0
The GidDy uP Kid The GidDy uP Kid 3 months ago
aDDed after hours sub $1 range...
πŸ‘οΈ0
aBeezlee aBeezlee 3 months ago
RS was unexpected for something without a delisting notice. Perhaps something planned to prevent a takeover. Hmm...
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...14A Filing...Approval of a series of alternate amendments to our Restated Certificate of Incorporation to effect, at the option of our Board of Directors, a reverse stock split of our common stock at a ratio in the range of 1-for-2 to 1-for-15, inclusive, with such ratio to be determined by our Board of Directors in its sole discretion (β€œReverse Stock Split Proposal” or β€œProposal 1”).
What if another matter is properly brought before the Special Meeting?
👍 1
georgie18 georgie18 3 months ago
TPST....85...A/H Dip...🥳
πŸ‘οΈ0
georgie18 georgie18 3 months ago
Nice to have you with me on it...🥳
πŸ‘οΈ0
tw0122 tw0122 3 months ago
One of your GM favorites been adding myself low $1s for next blastoff to $2s ...newsand trials
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$1.16s in the P/M...🥳

georgie18

Member Level
Re: georgie18 post# 614

Friday, October 25, 2024 12:38:28 PM

Post#
615
of 617
TPST...$1.12s clearing here...🥳Reversing...

georgie18

Member Level
Re: georgie18 post# 662364

Friday, October 25, 2024 9:43:40 AM

Post#
662715
of 662771
TPST...$1.08...Big Block Buys hitting here...🥳

georgie18

Member Level
Re: None

Wednesday, October 23, 2024 8:55:30 AM

Post#
613
of 613
TPST...Loaded $1.03 to $1.05s...🥳
πŸ‘οΈ0
aBeezlee aBeezlee 3 months ago
Long hold. Roche wouldn't supply them with goods if they felt phase 3 would fail. Looking for $2 on positive results.
πŸ‘οΈ0
georgie18 georgie18 3 months ago
Have a Great Weekend Y'all...🥳
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$1.12s clearing here...🥳Reversing...

georgie18

Member Level
Re: georgie18 post# 662364

Friday, October 25, 2024 9:43:40 AM

Post#
662715
of 662771
TPST...$1.08...Big Block Buys hitting here...🥳

georgie18

Member Level
Re: None

Wednesday, October 23, 2024 8:55:30 AM

Post#
613
of 613
TPST...Loaded $1.03 to $1.05s...🥳
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$1.08...Big Block Buys hitting here...🥳

georgie18

Member Level
Re: None

Wednesday, October 23, 2024 8:55:30 AM

Post#
613
of 613
TPST...Loaded $1.03 to $1.05s...🥳
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...Loaded $1.03 to $1.05s...🥳
πŸ‘οΈ0
Xunefox Xunefox 3 months ago
May be an AH show after all
πŸ‘οΈ0
aBeezlee aBeezlee 3 months ago
Yup TPST! I have RNAZ on list too. Buying both with next check. 🔥
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$1.22...🥳...Dipping it to fill the Open Gap...another great add spot...Ran to $1.60 range in the A/H ...

georgie18

Member Level
Re: georgie18 post# 384329

Tuesday, October 15, 2024 3:37:36 PM

Post#
384411
of 384426
TPST...$1.14clearing here...🥳

georgie18

Member Level
Re: None

Friday, October 11, 2024 9:46:27 AM

Post#
603
of 603
TPST...99...great add spot....🥳
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST …yes beauty move in the A/H…🥳
πŸ‘οΈ0
Vitamin310 Vitamin310 3 months ago
I’m in!
πŸ‘οΈ0
Money hunt Money hunt 3 months ago
TPST smell green dude!!! RNAZ Next DRUG
πŸ‘οΈ0
The GidDy uP Kid The GidDy uP Kid 3 months ago
Nice Georgie… TPST $1.61 after hours close…
πŸ‘οΈ0
aBeezlee aBeezlee 3 months ago
The next DRUG?!
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$1.14clearing here...🥳

georgie18

Member Level
Re: None

Friday, October 11, 2024 9:46:27 AM

Post#
603
of 603
TPST...99...great add spot....🥳
πŸ‘οΈ0
georgie18 georgie18 4 months ago
TPST...99...great add spot....🥳
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
TPST: Nope!! Cancer is NOT trending anymore, CLOWN!!! (Nice call, IDIOT!!!)
πŸ‘οΈ0
georgie18 georgie18 4 months ago
TPST...$1.09...Great add opportunity...imo...we shall see...🥳
πŸ‘οΈ0
georgie18 georgie18 4 months ago
TPST...$1.59...from the .90 range bottom...🥳BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced an agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.

georgie18

Member Level
Re: None

Friday, August 09, 2024 2:43:01 PM

Post#
652989
of 660804
TPST...$1.16...Taking a hit on earnings...adding more down here...🥳
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 months ago
july shelf offering allows lender to sell stock at anytime
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
TPST: Hopefully!! (But is "Cancer" TRENDING anymore??)
πŸ‘οΈ0
tw0122 tw0122 4 months ago
TPST 1.82 +’35% resistance at 1.85 looks good again until 2.01- 2.23 resistance then big jump to 2.91

a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.
Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study. This agreement builds on a clinical collaboration between the companies pursuant to which amezalpat was combined with atezolizumab and bevacizumab in first-line HCC patients and compared to atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study. Tempest retains all development and commercial rights to amezalpat.
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
TPST: I'm in!! Are you?? (Heck, goin' to Phase-3 with Roche?? I'll jump-on for ride!!)

πŸ‘οΈ0
Invest-in-America Invest-in-America 4 months ago
TPST: Some Roche agreement news.
πŸ‘οΈ0
georgie18 georgie18 4 months ago
TPST...$1.44s clearing on the 50MA Break...🥳
πŸ‘οΈ0
georgie18 georgie18 4 months ago
TPST...$1.50s clearing into the close...🥳
πŸ‘οΈ0
georgie18 georgie18 5 months ago
Have a Great Weekend Y'all...🥳
πŸ‘οΈ0
georgie18 georgie18 5 months ago
Nice...will be very pleased with 1/2 that target...🥳
πŸ‘οΈ0
glens0 glens0 5 months ago
Bought a starter today.
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
12:54 PM ET 8/15/24 | Dow Jones
πŸ‘οΈ0
georgie18 georgie18 5 months ago
TPST...$1.35...🥳
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock